Q2 2024 Tandem Diabetes Care Inc Earnings Call Transcript
Key Points
- Tandem Diabetes Care Inc (TNDM) reported a strong financial performance with a 12% worldwide sales growth in Q2 2024, reaching $222 million, marking the second highest sales quarter in the company's history.
- The launch of the Tandem Mobi pump platform has been successful, with strong demand and positive feedback from both users and healthcare providers.
- The company has seen a significant increase in new prescribers for Mobi, indicating an expanded prescriber audience and market penetration.
- Tandem Diabetes Care Inc (TNDM) has increased its 2024 sales guidance to a range of $885 million to $892 million, reflecting a 15% growth year-over-year.
- The company is making progress with new sensor integrations and international product launches, including the t:slim X2 with G7 integration, which is contributing to growth outside the US.
- Despite the positive sales growth, Tandem Diabetes Care Inc (TNDM) reported an adjusted EBITDA of negative 4% of sales for the first half of 2024.
- The company faced a recall for its t:slim iOS app due to a software issue, although it was quickly addressed, it remains an open recall.
- There is still uncertainty regarding the long-term trends of new product launches, as early data points may not be indicative of future performance.
- The company is facing competitive pressure, particularly from Medtronic, which is impacting competitive conversions.
- Gross margins are temporarily offset by higher manufacturing costs of Mobi at current volumes, although improvements are expected as volumes increase.
Good day and thank you for standing by. Welcome to Tandem Diabetes Care Quarter 2 2024 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Susan Morrison, Executive Vice President and Chief Administrative Officer. Please go ahead.
Hello, everyone, and thanks for joining Tandem's second quarter 2024 earnings call. Today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, our product pipeline, development timelines and financial performance and operating plans and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements. A list of factors that could cause actual results to be materially different from those expressed or implied by
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
